BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 34027867)

  • 21. Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
    Al-Batran SE; Homann N; Pauligk C; Illerhaus G; Martens UM; Stoehlmacher J; Schmalenberg H; Luley KB; Prasnikar N; Egger M; Probst S; Messmann H; Moehler M; Fischbach W; Hartmann JT; Mayer F; Höffkes HG; Koenigsmann M; Arnold D; Kraus TW; Grimm K; Berkhoff S; Post S; Jäger E; Bechstein W; Ronellenfitsch U; Mönig S; Hofheinz RD
    JAMA Oncol; 2017 Sep; 3(9):1237-1244. PubMed ID: 28448662
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low pan-immune-inflammation-value predicts better chemotherapy response and survival in breast cancer patients treated with neoadjuvant chemotherapy.
    Şahin AB; Cubukcu E; Ocak B; Deligonul A; Oyucu Orhan S; Tolunay S; Gokgoz MS; Cetintas S; Yarbas G; Senol K; Goktug MR; Yanasma ZB; Hasanzade U; Evrensel T
    Sci Rep; 2021 Jul; 11(1):14662. PubMed ID: 34282214
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic factors of perioperative FLOT regimen in operable gastric and gastroesophageal junction tumors: real-life data (Turkish Oncology Group).
    Erol C; Sakin A; Başoğlu T; Özden E; Çabuk D; Doğan M; Öksüzoğlu B; Yıldırım HÇ; Öner İ; Eryılmaz MK; Dülgar Ö; Aydın D; Doğan N; Özen M; Hacıbekiroğlu İ; Özdemir N; Gürler F; Paksoy N; Karabulut S; Aksoy A; Hızal M; Kahraman S; Şen E; Paydaş S; Çılbır E; Fırat F; Akdeniz N; Özçelik M; Oyman A; Baytemür NK; Acar R; Almuradova E; Karabulut B; Şakalar T; Arak H; Değerli E; Türker S; Alan Ö; Er Ö; Taşçı EŞ; Demir N; Çavdar E; Turhal S; Dede DŞ; Akıncı MB; Yalçın B; Yumuk F; Yalçın Ş; Şendur MAN
    Turk J Med Sci; 2022 Aug; 52(4):1022-1032. PubMed ID: 36326360
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pathological response and outcome after neoadjuvant chemotherapy with DOC (docetaxel, oxaliplatin, capecitabine) or EOF (epirubicin, oxaliplatin, 5-fluorouracil) for clinical T3-T4 non-metastatic gastric cancer.
    Petrioli R; Marrelli D; Roviello F; D'Ignazio A; Torre P; Chirra M; Savelli V; Ambrosio MR; Francini G; Calomino N; Farsi M; Vernillo R; Francini E
    Surg Oncol; 2020 Mar; 32():2-7. PubMed ID: 31670056
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In Gastric Cancer Patients Receiving Neoadjuvant Chemotherapy Systemic Inflammation Response Index is a Useful Prognostic Indicator.
    Chen L; Chen Y; Zhang L; Xue Y; Zhang S; Li X; Song H
    Pathol Oncol Res; 2021; 27():1609811. PubMed ID: 34712105
    [No Abstract]   [Full Text] [Related]  

  • 26. Prognostic value of platelet-associated biomarkers in rectal cancer patients received neoadjuvant chemoradiation: A retrospective study.
    Wang P; Wang Z; Liu Y; Xie J; Ren Y
    Cancer Radiother; 2021 Apr; 25(2):147-154. PubMed ID: 33423969
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.
    Al-Batran SE; Homann N; Pauligk C; Goetze TO; Meiler J; Kasper S; Kopp HG; Mayer F; Haag GM; Luley K; Lindig U; Schmiegel W; Pohl M; Stoehlmacher J; Folprecht G; Probst S; Prasnikar N; Fischbach W; Mahlberg R; Trojan J; Koenigsmann M; Martens UM; Thuss-Patience P; Egger M; Block A; Heinemann V; Illerhaus G; Moehler M; Schenk M; Kullmann F; Behringer DM; Heike M; Pink D; Teschendorf C; Löhr C; Bernhard H; Schuch G; Rethwisch V; von Weikersthal LF; Hartmann JT; Kneba M; Daum S; Schulmann K; Weniger J; Belle S; Gaiser T; Oduncu FS; Güntner M; Hozaeel W; Reichart A; Jäger E; Kraus T; Mönig S; Bechstein WO; Schuler M; Schmalenberg H; Hofheinz RD;
    Lancet; 2019 May; 393(10184):1948-1957. PubMed ID: 30982686
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Docetaxel, oxaliplatin, leucovorin, and 5-fluorouracil (FLOT) as preoperative and postoperative chemotherapy compared with surgery followed by chemotherapy for patients with locally advanced gastric cancer: a propensity score-based analysis.
    Wang K; Ren Y; Ma Z; Li F; Cheng X; Xiao J; Zhang S; Yu Z; Yang H; Zhou H; Li Y; Liu H; Jiao ZY
    Cancer Manag Res; 2019; 11():3009-3020. PubMed ID: 31114348
    [No Abstract]   [Full Text] [Related]  

  • 29. Comparison of neoadjuvant versus upfront surgery for treatment of locally advanced gastric cancer.
    Omarov N; Uymaz DS; Gurbuz B; Selcukbiricik F; Cigtaskin O; Yesilsoy M; Ozoran E; Balik E; Bugra D
    Ann Ital Chir; 2023; 94():569-579. PubMed ID: 37724662
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Feasibility of perioperative chemotherapy with infusional 5-FU, leucovorin, and oxaliplatin with (FLOT) or without (FLO) docetaxel in elderly patients with locally advanced esophagogastric cancer.
    Lorenzen S; Pauligk C; Homann N; Schmalenberg H; Jäger E; Al-Batran SE
    Br J Cancer; 2013 Feb; 108(3):519-26. PubMed ID: 23322206
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinical features and prognosis analysis of 21 gastric cancer patients with pathological complete response after neoadjuvant chemotherapy].
    Peng L; Yang W; Zhang Z; Liu H; Hua Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Oct; 20(10):1168-1173. PubMed ID: 29130233
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic Role of Peripheral Neutrophil-Lymphocyte Ratio (NLR) and Platelet-Lymphocyte Ratio (PLR) in Patients with Rectal Cancer Undergoing Neoadjuvant Chemoradiotherapy.
    Ergen ŞA; Barlas C; Yıldırım C; Öksüz DÇ
    J Gastrointest Cancer; 2022 Mar; 53(1):151-160. PubMed ID: 33392960
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Platelet/Lymphocyte Ratio Is Superior to Neutrophil/Lymphocyte Ratio as a Predictor of Chemotherapy Response and Disease-free Survival in Luminal B-like (HER2
    Hu Y; Wang S; Ding N; Li N; Huang J; Xiao Z
    Clin Breast Cancer; 2020 Aug; 20(4):e403-e409. PubMed ID: 32201163
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio associated with prognosis in patients with HER2-positive early breast cancer receiving adjuvant trastuzumab?
    Ulas A; Avci N; Kos T; Cubukcu E; Olmez OF; Bulut N; Degirmenci M
    J BUON; 2015; 20(3):714-22. PubMed ID: 26214622
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dose-finding study of modified FLOT (mFLOT) regimen as first-line treatment in Chinese patients with metastatic adenocarcinoma of stomach.
    Zhou C; Ma T; Shi M; Xi W; Wu J; Yang C; Zhu Z; Zhang J
    Cancer Chemother Pharmacol; 2020 Jan; 85(1):113-119. PubMed ID: 31691079
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Predictive and Prognostic significance of high-sensitivity modified Glasgow Prognostic Score (HS-mGPS) in advanced gastric cancer patients treated with neoadjuvant chemotherapy].
    Cui Y; Li J; Cao YH; Liu MY; Shi ZX; Gao TH
    Zhonghua Zhong Liu Za Zhi; 2017 Mar; 39(3):195-200. PubMed ID: 28316218
    [No Abstract]   [Full Text] [Related]  

  • 37. Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis.
    Nishimura R; Osako T; Okumura Y; Hayashi M; Arima N
    Breast Cancer; 2010 Oct; 17(4):269-75. PubMed ID: 19730975
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The safety and efficacy of fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) combination in the front-line treatment for patients with advanced gastric or gastroesophageal adenocarcinoma: phase II trial.
    Anter AH; Abdel-Latif RM
    Med Oncol; 2013 Mar; 30(1):451. PubMed ID: 23307258
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
    Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
    World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of outcomes in inflammatory breast cancer.
    Al Jarroudi O; El Bairi K; Abda N; Zaimi A; Jaouani L; Chibani H; Afqir S
    Biomark Med; 2021 Oct; 15(14):1289-1298. PubMed ID: 34486882
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.